Microbot Medical Net Worth
Microbot Medical Net Worth Breakdown | MBOT |
Microbot Medical Net Worth Analysis
Microbot Medical's net worth analysis, or its valuation, is the process of determining the total value of the company. This involves assessing a range of factors, including Microbot Medical's financial performance, assets, liabilities, and potential for growth. The ultimate goal is to provide a clear understanding of Microbot Medical's overall worth, which can help investors make informed investment decisions. There are several methods that can be used to perform Microbot Medical's net worth analysis. One common approach is to calculate Microbot Medical's market capitalization.Another approach is to use the price-to-earnings ratio (P/E ratio), which compares Microbot Medical's stock price to its earnings per share (EPS). Discounted cash flow (DCF) analysis is another popular method for assessing Microbot Medical's net worth. This approach calculates the present value of Microbot Medical's future cash flows, taking into account factors such as growth rate, profitability, and risk. By comparing the present value of Microbot Medical's cash flows to its current stock price, investors can gain a better understanding of the company's overall value. Finally, investors may use comparable company analysis to evaluate Microbot Medical's net worth. This involves comparing Microbot Medical's financial metrics to similar companies in the same industry. By identifying companies with similar financial characteristics, investors can gain insight into Microbot Medical's net worth relative to its peers.
Enterprise Value |
|
To determine if Microbot Medical is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Microbot Medical's net worth research are outlined below:
| Microbot Medical generated a negative expected return over the last 90 days | |
| Microbot Medical has some characteristics of a very speculative penny stock | |
| Net Loss for the year was (10.74 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Microbot Medical currently holds about 9.29 M in cash with (8.53 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.31, which can makes it an attractive takeover target, given it will continue generating positive cash flow. |
Microbot Medical uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Microbot Medical. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Microbot Medical's previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 29th of March 2024 Upcoming Quarterly Report | View | |
| 15th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 29th of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Know Microbot Medical's Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Microbot Medical is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Microbot Medical backward and forwards among themselves. Microbot Medical's institutional investor refers to the entity that pools money to purchase Microbot Medical's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Two Sigma Securities, Llc | 2024-06-30 | 11.4 K | Susquehanna International Group, Llp | 2024-06-30 | 10.4 K | Stifel Financial Corp | 2024-06-30 | 10.3 K | Diamant Asset Management Inc | 2024-06-30 | 10 K | Tower Research Capital Llc | 2024-06-30 | 6.8 K | Beacon Capital Management, Llc | 2024-09-30 | 6 K | Bfsg, Llc | 2024-09-30 | 5.5 K | Group One Trading, Lp | 2024-06-30 | 4.6 K | Steward Partners Investment Advisory, Llc | 2024-06-30 | 2.3 K | Vanguard Group Inc | 2024-09-30 | 459.5 K | Blackrock Inc | 2024-06-30 | 137.4 K |
Follow Microbot Medical's market capitalization trends
The company currently falls under 'Micro-Cap' category with a current market capitalization of 15.74 M.Market Cap |
|
Project Microbot Medical's profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (1.29) | (1.23) | |
| Return On Capital Employed | (2.17) | (2.06) | |
| Return On Assets | (1.29) | (1.23) | |
| Return On Equity | (2.39) | (2.27) |
When accessing Microbot Medical's net worth, it's important to look at multiple sources and consider different scenarios. For example, gross profit margin measures Microbot Medical's profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Microbot Medical's profitability and make more informed investment decisions.
Please note, the imprecision that can be found in Microbot Medical's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Microbot Medical. Check Microbot Medical's Beneish M Score to see the likelihood of Microbot Medical's management manipulating its earnings.
Evaluate Microbot Medical's management efficiency
Microbot Medical has return on total asset (ROA) of (0.6488) % which means that it has lost $0.6488 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.3446) %, meaning that it created substantial loss on money invested by shareholders. Microbot Medical's management efficiency ratios could be used to measure how well Microbot Medical manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to gain to -1.23 in 2024. Return On Capital Employed is likely to gain to -2.06 in 2024. Total Current Liabilities is likely to gain to about 4.8 M in 2024, whereas Liabilities And Stockholders Equity is likely to drop slightly above 7.9 M in 2024.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 0.44 | 0.42 | |
| Tangible Book Value Per Share | 0.44 | 0.42 | |
| Enterprise Value Over EBITDA | (1.36) | (1.43) | |
| Price Book Value Ratio | 3.72 | 3.90 | |
| Enterprise Value Multiple | (1.36) | (1.43) | |
| Price Fair Value | 3.72 | 3.90 | |
| Enterprise Value | 14.5 M | 28.5 M |
The management team at Microbot Medical has a track record of steering the company towards sustained growth. Evaluating their strategies helps in understanding the stock's long-term potential.
Return On Equity (1.34) |
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Microbot Medical insiders, such as employees or executives, is commonly permitted as long as it does not rely on Microbot Medical's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Microbot Medical insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Yoseph Bornstein over three months ago Disposition of 45000 shares by Yoseph Bornstein of Microbot Medical at 1.0733 subject to Rule 16b-3 | ||
Yoseph Bornstein over three months ago Disposition of 32067 shares by Yoseph Bornstein of Microbot Medical at 1.03 subject to Rule 16b-3 | ||
Yoseph Bornstein over three months ago Disposition of 44159 shares by Yoseph Bornstein of Microbot Medical at 1.0372 subject to Rule 16b-3 | ||
Harel Gadot over six months ago Acquisition by Harel Gadot of 79567 shares of Microbot Medical at 1.25 subject to Rule 16b-3 | ||
Wenderow Tal Baruch over a year ago Acquisition by Wenderow Tal Baruch of 74218 shares of Microbot Medical subject to Rule 16b-3 | ||
Weissman Irving over a year ago Acquisition by Weissman Irving of 6068 shares of Microbot Medical subject to Rule 16b-3 |
Microbot Medical Earnings per Share Projection vs Actual
Microbot Medical Corporate Management
| Rachel Vaknin | Chief Officer | Profile | |
| Eyal MD | Chief Board | Profile | |
| Pr DSc | Scientific CoFounder | Profile | |
| Juan DiazCartelle | Chief Officer | Profile |
Additional Tools for Microbot Stock Analysis
When running Microbot Medical's price analysis, check to measure Microbot Medical's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Microbot Medical is operating at the current time. Most of Microbot Medical's value examination focuses on studying past and present price action to predict the probability of Microbot Medical's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Microbot Medical's price. Additionally, you may evaluate how the addition of Microbot Medical to your portfolios can decrease your overall portfolio volatility.